Trial Profile
Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jan 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms Yervoy RMP
- Sponsors Bristol-Myers Squibb
- 11 Jan 2022 Status changed from recruiting to completed.
- 23 Jan 2017 Planned End Date changed from 1 Jul 2020 to 1 Dec 2019.
- 23 Jan 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Dec 2019.